PHATHOM PHARMACEUTICALS, INC. Selling, General and Administrative Expense
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Selling, General and Administrative Expense of $55.33 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $55.33M, a 35.14% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $54.01M, a 42.83% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $48.37M, a 36.92% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $51.56M, a 32.25% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2025 was $279.72M, a 3.77% decline from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2024 was $290.66M, a 146.48% increase from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2023 was $117.93M, a 16.76% increase from fiscal 2022.
- PHATHOM PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2022 was $101.00M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $55.33M 10-Q · filed 2026-07-30 | $109.34M 10-Q · filed 2026-07-30 | $157.71M derived: sum of 3 quarters · filed 2026-07-30 | $209.27M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $54.01M 10-Q · filed 2026-04-30 | $102.38M derived: sum of 2 quarters · filed 2026-04-30 | $153.94M derived: sum of 3 quarters · filed 2026-04-30 | $239.25M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $48.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $99.93M derived: sum of 2 quarters · filed 2026-02-26 | $185.24M derived: sum of 3 quarters · filed 2026-07-30 | $279.72M 10-K · filed 2026-02-26 |
| 2025-09-30 | $51.56M 10-Q · filed 2025-10-30 | $136.87M derived: sum of 2 quarters · filed 2026-07-30 | $231.35M 10-Q · filed 2025-10-30 | $308.03M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $85.31M 10-Q · filed 2026-07-30 | $179.79M 10-Q · filed 2026-07-30 | $256.47M derived: sum of 3 quarters · filed 2026-07-30 | $332.57M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $94.47M 10-Q · filed 2026-04-30 | $171.16M derived: sum of 2 quarters · filed 2026-04-30 | $247.26M derived: sum of 3 quarters · filed 2026-04-30 | $323.13M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $76.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $152.78M derived: sum of 2 quarters · filed 2026-02-26 | $228.65M derived: sum of 3 quarters · filed 2026-02-26 | $290.66M 10-K · filed 2026-02-26 |
| 2024-09-30 | $76.10M 10-Q · filed 2025-10-30 | $151.97M derived: sum of 2 quarters · filed 2025-10-30 | $213.98M 10-Q · filed 2025-10-30 | $270.98M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $75.87M 10-Q · filed 2025-08-07 | $137.88M 10-Q · filed 2025-08-07 | $194.88M derived: sum of 3 quarters · filed 2025-08-07 | $218.27M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $62.01M 10-Q · filed 2025-05-01 | $119.01M derived: sum of 2 quarters · filed 2025-05-01 | $142.40M derived: sum of 3 quarters · filed 2025-05-01 | $161.34M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $57.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $80.39M derived: sum of 2 quarters · filed 2025-03-06 | $99.33M derived: sum of 3 quarters · filed 2025-03-06 | $117.93M 10-K · filed 2025-03-06 |
| 2023-09-30 | $23.40M 10-Q · filed 2024-11-07 | $42.33M derived: sum of 2 quarters · filed 2024-11-07 | $60.93M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $18.94M 10-Q · filed 2024-08-08 | $37.54M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $18.60M 10-Q/A · filed 2024-06-14 | |||
| 2022-12-31 | $101.00M 10-K/A · filed 2024-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |